A detailed history of Kayne Anderson Rudnick Investment Management LLC transactions in Amgen Inc stock. As of the latest transaction made, Kayne Anderson Rudnick Investment Management LLC holds 24,751 shares of AMGN stock, worth $7.82 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
24,751
Previous 27,864 11.17%
Holding current value
$7.82 Million
Previous $7.92 Million 2.39%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$262.75 - $319.31 $817,940 - $994,012
-3,113 Reduced 11.17%
24,751 $7.73 Million
Q1 2024

May 14, 2024

SELL
$268.87 - $324.56 $667,604 - $805,882
-2,483 Reduced 8.18%
27,864 $7.92 Million
Q4 2023

Feb 13, 2024

SELL
$255.7 - $288.46 $472,533 - $533,074
-1,848 Reduced 5.74%
30,347 $8.74 Million
Q3 2023

Nov 13, 2023

SELL
$218.65 - $271.46 $48,103 - $59,721
-220 Reduced 0.68%
32,195 $8.65 Million
Q2 2023

Aug 11, 2023

SELL
$214.27 - $253.37 $2.48 Million - $2.94 Million
-11,592 Reduced 26.34%
32,415 $7.2 Million
Q1 2023

May 16, 2023

BUY
$225.79 - $275.2 $135,022 - $164,569
598 Added 1.38%
44,007 $10.6 Million
Q4 2022

Feb 13, 2023

SELL
$229.03 - $291.01 $796,566 - $1.01 Million
-3,478 Reduced 7.42%
43,409 $11.4 Million
Q3 2022

Nov 16, 2022

BUY
$224.46 - $253.15 $10.5 Million - $11.9 Million
46,887 New
46,887 $10.6 Million
Q3 2022

Nov 14, 2022

SELL
$224.46 - $253.15 $5.42 Million - $6.12 Million
-24,159 Closed
0 $10.6 Million
Q2 2022

Aug 12, 2022

BUY
$230.71 - $256.74 $35,990 - $40,051
156 Added 0.65%
24,159 $5.88 Million
Q1 2022

May 16, 2022

BUY
$219.27 - $242.57 $1.04 Million - $1.15 Million
4,752 Added 24.68%
24,003 $5.8 Million
Q4 2021

Feb 14, 2022

SELL
$198.88 - $227.6 $280,221 - $320,688
-1,409 Reduced 6.82%
19,251 $4.33 Million
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $911,699 - $1.07 Million
-4,295 Reduced 17.21%
20,660 $4.4 Million
Q2 2021

Aug 13, 2021

BUY
$233.58 - $259.14 $234,747 - $260,435
1,005 Added 4.2%
24,955 $6.08 Million
Q1 2021

May 17, 2021

BUY
$221.91 - $258.6 $110,511 - $128,782
498 Added 2.12%
23,950 $5.96 Million
Q4 2020

Feb 12, 2021

BUY
$216.38 - $257.67 $415,233 - $494,468
1,919 Added 8.91%
23,452 $5.39 Million
Q3 2020

Nov 16, 2020

SELL
$234.65 - $260.95 $962,534 - $1.07 Million
-4,102 Reduced 16.0%
21,533 $5.47 Million
Q2 2020

Aug 14, 2020

SELL
$197.81 - $242.74 $1.03 Million - $1.27 Million
-5,212 Reduced 16.9%
25,635 $6.05 Million
Q1 2020

May 15, 2020

SELL
$182.24 - $241.7 $1.3 Million - $1.73 Million
-7,139 Reduced 18.79%
30,847 $6.25 Million
Q4 2019

Feb 13, 2020

SELL
$189.21 - $243.2 $178,614 - $229,580
-944 Reduced 2.42%
37,986 $9.16 Million
Q3 2019

Nov 14, 2019

SELL
$174.11 - $208.62 $159,658 - $191,304
-917 Reduced 2.3%
38,930 $7.53 Million
Q2 2019

Aug 14, 2019

BUY
$166.7 - $195.41 $111,188 - $130,338
667 Added 1.7%
39,847 $7.34 Million
Q1 2019

Jun 12, 2019

SELL
$180.87 - $203.88 $65,836 - $74,212
-364 Reduced 0.92%
39,180 $7.44 Million
Q1 2019

May 10, 2019

SELL
$180.87 - $203.88 $189,190 - $213,258
-1,046 Reduced 2.58%
39,544 $7.51 Million
Q4 2018

Feb 06, 2019

SELL
$178.4 - $208.25 $85,988 - $100,376
-482 Reduced 1.17%
40,590 $7.9 Million
Q3 2018

Nov 13, 2018

SELL
$185.29 - $208.89 $257,738 - $290,565
-1,391 Reduced 3.28%
41,072 $8.52 Million
Q2 2018

Aug 13, 2018

BUY
$166.05 - $186.51 $123,043 - $138,203
741 Added 1.78%
42,463 $7.84 Million
Q1 2018

May 09, 2018

BUY
$169.43 - $198.0 $1.24 Million - $1.45 Million
7,348 Added 21.38%
41,722 $7.11 Million
Q4 2017

Feb 12, 2018

BUY
$168.79 - $188.59 $117,140 - $130,881
694 Added 2.06%
34,374 $5.98 Million
Q3 2017

Nov 07, 2017

BUY
$167.29 - $191.0 $5.63 Million - $6.43 Million
33,680
33,680 $6.28 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Kayne Anderson Rudnick Investment Management LLC Portfolio

Follow Kayne Anderson Rudnick Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kayne Anderson Rudnick Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kayne Anderson Rudnick Investment Management LLC with notifications on news.